Table 1.
Demographic and clinical characteristics of PD patients and healthy controls.
| G2385R carriers | G2385R non‐carriers | Healthy controls | P value | |
|---|---|---|---|---|
| n = 12 | n = 47 | n = 30 | ||
| Age (years) | 63.00 ± 7.92 | 59.91 ± 8.84 | 58.73 ± 8.33 | 0.365 1 , 0.137 2 , 0.274 3 |
| Gender, male, n (%) | 4 (33.3%) | 23 (48.9%) | 16 (53.3%) | 0.333 1 , 0.241 2 , 0.707 3 |
| BMI | 25.25 ± 4.39 | 25.09 ± 3.16 | 25.05 ± 2.98 | 0.883 1 , 0.887 2 , 0.961 3 |
| Age of onset (years) | 57.83 ± 9.27 | 55.89 ± 9.70 | / | 0.665 |
| Symptoms of onset | ||||
| Resting tremor, n (%) | 5 (41.7%) | 21 (44.7%) | / | 0.851 |
| Bradykinesia‐rigidity, n (%) | 4 (33.3%) | 19 (40.4%) | / | 0.906 4 |
| Mixed symptoms, n (%) | 2 (16.7%) | 5 (10.64%) | / | 0.939 4 |
| Others, n (%) | 1 (8.33%) | 2 (4.26%) | / | 1.000 4 |
| Disease duration (years) | 5.17 ± 4.24 | 4.12 ± 3.10 | / | 0.461 |
| Hoehn & Yahr stage | 2.58 ± 0.73 | 2.35 ± 0.62 | / | 0.132 5 |
| MDS‐UPDRSⅢ score | 52.17 ± 26.29 | 36.55 ± 17.82 | / | 0.072 |
| Annual UPDRS‐III progression | 13.33 ± 6.50 | 15.57 ± 18.57 | / | 0.684 |
| Non‐motor symptoms, n (%) | 12 (100%) | 46 (97.87%) | / | 1.000 6 |
| NMSS score | 56.92 ± 21.37 | 29.87 ± 22.56 | / | <0.001 * |
| RBD, n (%) | 8 (66.7%) | 11 (23.4%) | / | 0.0124 |
| MMSE score | 27.42 ± 1.62 | 26.40 ± 2.10 | / | 0.121 |
| Response well to L‐Dopa, n (%) | 9 (75.0%) | 26 (55.3%) | / | 1.000 4 |
| LED (mg/day) | 512.5 ± 190.54 | 346.01 ± 138.27 | / | 0.001 * |
Others: weakness, pain, or constipation; PD, Parkinson disease; BMI, body mass index; MDS‐UPDRSIII, Movement Disorder Society Unified Parkinson’s Disease Ranking Scale part III; NMSS, Nonmotor Symptoms Scale; RBD, rapid eye movement sleep behavior disorder; LED, levodopa equivalent dose; /, none.
*
indicates the significant difference.
1
G2385R carriers versus G2385R noncarriers.
2
G2385R carriers versus Healthy Control.
3
G2385R noncarriers versus Healthy Control.
4
Continuous correction chi‐square test.
5
Mann–Whitney U test.
6
Fisher’s exact test.